Trial reportNutrients2022
Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans.
Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 58 citations in OpenAlex.
- Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection.The Journal of infectious diseases · 2025Trial
- Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis.Journal of Crohn's & colitis · 2025Trial
- The Roles of Gut Microbiota in the Pathogenesis of Acute Pancreatitis.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility.Journal of advanced research · 2026Review
- The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications.Communications biology · 2026Review
- Gut-bone axis crosstalk: Microbiota-driven immune-metabolic-neural networks in bone disorders and precision interventions.Journal of orthopaedic translation · 2026Review
- Metabolic syndrome and a broken heart: trust your gut or risk your heart.American journal of physiology. Heart and circulatory physiology · 2026Review
- Tanshinones fromActa biochimica et biophysica Sinica · 2026Article
- Bacteroides ovatus Has the Potential to Be a Next-Generation Probiotic Strain.Probiotics and antimicrobial proteins · 2026Review
- Improving Growth Dynamics ofInternational journal of molecular sciences · 2026Article
- Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism.Frontiers in immunology · 2026Review
- Genome-resolved gut metagenomics identifies anFrontiers in immunology · 2026Article
- Bile Acids: The Contribution of the Gut Microbiota to Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Gut microbiota in obesity management: from microbial clocks to precision microbial therapies.Frontiers in cellular and infection microbiology · 2026Review
- Classification of intestinal inflammation driven by gut microbiota metabolites: a new paradigm for precision treatment of cardiovascular diseases.Frontiers in microbiology · 2026Review
- Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content.Gut microbes · 2025Article
- Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles.NPJ biofilms and microbiomes · 2025Review
- Integrated analysis of gut microbiota, fecal and serum metabolites in type 2 diabetes mellitus with peripheral neuropathy.Journal of endocrinological investigation · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Fecal microbiota transplantation (FMT) is a promising therapeutic modality for the treatment and prevention of metabolic disease. We previously conducted a double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients in which we found that FMT enhanced gut bacterial bile acid metabolism and delayed the development of impaired glucose tolerance relative to the placebo control group. Therefore, we conducted a secondary analysis of fecal samples collected from these patients to assess the potential gut microbial species contributing to the effect of FMT to improve metabolic health and increase gut bacterial bile acid metabolism. Fecal samples collected at baseline and after 4 weeks of FMT or placebo treatment underwent shotgun metagenomic analysis. Ultra-high-performance liquid chromatography-mass spectrometry was used to profile fecal bile acids. FMT-enriched bacteria that have been implicated in gut bile acid metabolism included
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.